Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Risedronate for the Treatment of Osteoporosis for People With Spinal Cord Injury

This study has been completed.
The Physicians' Services Incorporated Foundation
St. Joseph's Health Care London
Information provided by:
Toronto Rehabilitation Institute Identifier:
First received: August 29, 2005
Last updated: October 12, 2010
Last verified: July 2008
The purpose of this study is to find out if risedronate works for the treatment of osteoporosis for people with spinal cord injury.

Condition Intervention Phase
Drug: Risedronate
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Risedronate for Treatment of Sublesional Osteoporosis After Spinal Cord Injury

Resource links provided by NLM:

Further study details as provided by Toronto Rehabilitation Institute:

Primary Outcome Measures:
  • Change in bone mineral density of the distal femur between baseline and 18-months [ Time Frame: 18 months ]

Secondary Outcome Measures:
  • Change in bone mineral density of the hips and proximal tibia between baseline and 18-months [ Time Frame: 18 months ]
  • The change in biochemical bone markers of bone turnover between baseline and 18-months [ Time Frame: 18 months ]
  • The frequency and severity of adverse events [ Time Frame: 18 months ]

Estimated Enrollment: 46
Study Start Date: November 2004
Study Completion Date: March 2009
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Traumatic spinal cord injury of greater than 18 months
  • Osteopenia or osteoporosis of the hip
  • Must be able to swallow tablets and sit upright

Exclusion Criteria:

  • Bilateral heterotopic ossification
  • Bilateral lower extremity metal implants
  • Pregnant or lactating females
  • Paget's disease
  • Osteomalacia
  • Steroid induced bone loss
  • Untreated parathyroid or thyroid disease
  • Symptomatic hypocalcemia or hypophosphatemia
  • Treatment in the last year with calcitonin, fluoride or anabolic steroids
  • Current treatment with prednisone
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00138866

Canada, Ontario
Toronto Rehab, Lyndhurst Centre
Toronto, Ontario, Canada, M4G 3V9
Sponsors and Collaborators
Toronto Rehabilitation Institute
The Physicians' Services Incorporated Foundation
St. Joseph's Health Care London
Principal Investigator: B. Cathy Craven, MD, FRCPC Toronto Rehabilitation Institute
  More Information

Responsible Party: Dr. BC Craven, Toronto Rehab Institute Identifier: NCT00138866     History of Changes
Other Study ID Numbers: TRI REB #04-016
PSI #03-52
Study First Received: August 29, 2005
Last Updated: October 12, 2010

Keywords provided by Toronto Rehabilitation Institute:
Spinal cord injury

Additional relevant MeSH terms:
Spinal Cord Injuries
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
Trauma, Nervous System
Wounds and Injuries
Risedronate Sodium
Etidronic Acid
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Bone Density Conservation Agents
Physiological Effects of Drugs processed this record on May 23, 2017